拱东医疗(605369) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 reached CNY 27,191.85 million, representing a year-on-year increase of 20.22%[4] - Net profit attributable to shareholders was CNY 4,510.90 million, reflecting a significant growth of 56.02% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 85.73% to CNY 4,344.50 million[4] - Basic and diluted earnings per share were both CNY 0.40, marking an increase of 53.85%[4] - The improvement in net profit was attributed to increased operating revenue and a decrease in expense ratios, along with better performance from the U.S. subsidiary Trademark Plastics Inc.[8] - Operating profit for Q1 2024 reached CNY 52,139,285.72, up from CNY 34,853,504.65 in the same period last year, indicating a growth of 49.5%[20] - Total comprehensive income for Q1 2024 was CNY 45,225,492.33, compared to CNY 25,517,378.92 in Q1 2023, reflecting an increase of 77.5%[21] - The company recorded investment income of CNY 2,543,115.69 in Q1 2024, compared to CNY 1,987,849.44 in Q1 2023, representing a growth of 27.8%[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 193,075.15 million, up 2.83% from the end of the previous year[5] - Shareholders' equity attributable to shareholders increased to CNY 168,376.45 million, a rise of 2.76% compared to the previous year[5] - The total liabilities as of March 31, 2024, were ¥246,987,043.09, compared to ¥239,146,257.53 at the end of 2023, marking a rise of 3.6%[16] - The company's retained earnings increased to ¥749,778,090.97 in Q1 2024 from ¥704,669,107.28 in Q4 2023, a growth of 6.4%[16] Cash Flow - The company reported a net cash flow from operating activities of CNY 4,106.50 million, an increase of 8.11% year-on-year[4] - Cash flow from operating activities generated a net inflow of CNY 41,065,035.92, compared to CNY 37,984,850.73 in Q1 2023, showing an increase of 5.7%[25] - The company's cash and cash equivalents as of March 31, 2024, amounted to ¥463,485,215.80, compared to ¥447,676,567.18 at the end of 2023, indicating a 3.6% increase[13] - The company reported cash and cash equivalents at the end of Q1 2024 amounting to CNY 413,485,215.80, a slight decrease from CNY 423,557,383.16 at the end of Q1 2023[26] Costs and Expenses - Total operating costs for Q1 2024 were ¥222,178,192.97, up from ¥197,091,988.48 in Q1 2023, reflecting a growth of 12.7%[19] - Research and development expenses for Q1 2024 were ¥11,134,804.13, down from ¥16,291,868.49 in Q1 2023, indicating a decrease of 31.7%[19] - The company incurred a credit impairment loss of CNY -975,657.00 in Q1 2024, compared to a gain of CNY 1,694,567.02 in Q1 2023[20] Inventory and Receivables - Accounts receivable increased to ¥236,187,069.01 in Q1 2024 from ¥223,520,318.99 in Q4 2023, showing a rise of 5.4%[14] - Inventory decreased to ¥111,174,726.17 in Q1 2024 from ¥125,318,459.62 in Q4 2023, a decline of 11.3%[14]